Craig L Slingluff, Jr

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Craig L Slingluff, Jr sits in the top decile of US sponsors by registered trial count (#668 of 15,742 sponsors by registered trial count).

23 total trials 1 currently recruiting 14 completed early-phase tilt top decile by trial count

Craig L Slingluff, Jr: 23 sponsored US clinical trials, 1 recruiting.

Craig L Slingluff, Jr sponsors 23 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 14 completed. 0 of these trials are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Melanoma, with 3 trials.

Top-decile sponsor footprint

Craig L Slingluff, Jr ranks in the top decile of sponsors by registered trial count (#668 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 0/100

14 of 22 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (63.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

23 total, page 1 of 1

RECRUITING NA

Excision of Lymph Node Trial (EXCILYNT) (Mel69)

NCT05839912
COMPLETED Phase 1

Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)

NCT04364230
TERMINATED Phase 1

Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors

NCT04116320
COMPLETED Phase 1

Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma

NCT03617328
COMPLETED Phase 1

Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab

NCT02515227
TERMINATED Early Phase 1

A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib

NCT02382549
TERMINATED Phase 1

Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma

NCT02425306
TERMINATED Phase 1

A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma

NCT02385669
COMPLETED Phase 1

Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists

NCT02126579
COMPLETED Phase 1

Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies

NCT01846143
COMPLETED Phase 1

A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients

NCT01585350
TERMINATED Phase 1

Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer

NCT01532960
COMPLETED Early Phase 1

Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI

NCT01425749
TERMINATED Phase 1

Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma

NCT00977145
COMPLETED Phase 1

Evaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer

NCT00892567
COMPLETED Phase 1

Vaccine Therapy in Treating Patients With Advanced Melanoma

NCT00705640
TERMINATED Phase 2

Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

NCT00373217
COMPLETED Phase 1

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

NCT00118274
COMPLETED Phase 1

Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

NCT00118313
COMPLETED Phase 2

Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

NCT00089193
TERMINATED Early Phase 1

Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV Colorectal Cancer

NCT00091286
COMPLETED Phase 2

Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma

NCT00938223
COMPLETED NA

Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma

NCT00912418

Phase Distribution

PhaseTrial count
Phase 1 18
Phase 2 3

Therapeutic Areas

Melanoma 3
Mucosal Melanoma 1
Breast Neoplasms 1
Melanoma (Skin) 1
Metastatic Melanoma 1

What is open in the Craig L Slingluff, Jr pipeline

1 recruiting of 23 indexed (4% open); 14 completed (61%).

Phase mix: 0 late (III/IV) vs 21 early (I/II) (early-phase heavy).

Top condition: Melanoma (3 trials), 4 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Craig L Slingluff, Jr: open-pipeline peers nationwide

Peers matched on 23 registered trials and 4% open enrollment, not the therapeutic-area sidebar.

Craig L Slingluff, Jr sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 050100150200 0%5%10%15%20%25% Total trials Recruiting share Craig L Slingluff, JrAMAG PharmaceuticalsAtriCureCara TherapeuticsDuramed ResearchEsperion TherapeuticsTonix PharmaceuticalsRockefeller UniversityGalderma R&D
Craig L Slingluff, Jr sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Craig L Slingluff, Jr sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 23 trials (± recruiting share)

Sponsors near 4% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Craig L Slingluff, Jr page

23 registered trials is a research-attention snapshot, not an endorsement of Craig L Slingluff, Jr or any single study.

  • 1 of Craig L Slingluff, Jr's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Melanoma is the condition Craig L Slingluff, Jr studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Melanoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Craig L Slingluff, Jr pipeline card: 23 registered trials from official public datasets.Report a data error.